Drug profile · INN
atracurium besylate
ATRACURIUM BESYLATE PRESERVATIVE FREE
atracurium besylate (ATRACURIUM BESYLATE PRESERVATIVE FREE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Drug details — atracurium besylate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
atracurium besylate (ATRACURIUM BESYLATE PRESERVATIVE FREE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscle-type nicotinic acetylcholine receptor antagonist
Primary target: Muscle-type nicotinic acetylcholine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is atracurium besylate?
atracurium besylate (ATRACURIUM BESYLATE PRESERVATIVE FREE) is a muscle-type nicotinic acetylcholine receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for atracurium besylate?
ATRACURIUM BESYLATE PRESERVATIVE FREE is a marketed brand name for atracurium besylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atracurium besylate?
atracurium besylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.